Lp(a) Basics: Structure, Function, and Genetics

Introduction

Lipoprotein(a), or Lp(a), is arguably the most underrecognized major cardiovascular risk factor. Unlike LDL cholesterol, which responds readily to statins and lifestyle changes, Lp(a) levels are largely fixed at birth by your genetic inheritance. Roughly 20% of the global population has elevated Lp(a), placing them at increased risk for heart attack, stroke, peripheral artery disease, and aortic valve stenosis.

This article explains what Lp(a) is, how it differs structurally from other lipoproteins, why it evolved in humans, and how genetic variation determines your level. Understanding these basics provides the foundation for interpreting your own Lp(a) test results and making sense of the treatment options available today and on the horizon.

What is Lp(a) and how does it differ from LDL?

Lp(a) is a specialized lipoprotein particle that resembles LDL in many ways but carries an additional protein that fundamentally changes its behavior. Like LDL, Lp(a) contains a core of cholesterol esters surrounded by a phospholipid shell, with a single apolipoprotein B-100 molecule anchoring the structure. What distinguishes Lp(a) is a second protein called apolipoprotein(a), which attaches to the apoB via a disulfide bond.

Apolipoprotein(a) is structurally similar to plasminogen, a key protein in the body’s clot-dissolving system. This resemblance isn’t coincidental. Apo(a) contains multiple copies of structures called kringle domains, particularly kringle IV type 2 repeats, which vary in number between individuals. The number of these repeats determines apo(a) isoform size, which inversely correlates with Lp(a) concentration in the blood (Clarke et al., 2009).

The practical consequence is that Lp(a) combines the atherogenic properties of an LDL-like particle with unique prothrombotic characteristics from its plasminogen-like component. This dual nature explains why Lp(a) poses risks that extend beyond cholesterol delivery to arterial walls.

What is the function of apolipoprotein(a)?

The evolutionary purpose of apolipoprotein(a) remains debated. Apo(a) is found only in humans, old-world primates, and hedgehogs, suggesting it arose relatively recently in evolutionary terms. Some researchers hypothesize it developed as a wound-healing mechanism, helping to deliver cholesterol to sites of tissue repair while simultaneously preventing excessive bleeding.

Apo(a) carries oxidized phospholipids on its surface, which may have served as a primitive immune function by neutralizing pathogens. The oxidized phospholipids on Lp(a) promote inflammation and contribute to the progression of both atherosclerosis and calcific aortic valve disease (Capoulade et al., 2015). What may have been protective in ancestral environments now contributes to chronic disease in modern contexts.

The bottom line is that apo(a) likely served beneficial roles in infection defense and wound healing when human lifespans were shorter and cardiovascular disease was rare. In contemporary populations living long enough to develop atherosclerosis, these same properties become harmful.

How does Lp(a) particle size affect risk?

The LPA gene exhibits remarkable variability in the number of kringle IV type 2 repeats it encodes. This copy number variation produces apo(a) proteins ranging from very small (few repeats) to very large (many repeats). Smaller apo(a) isoforms are associated with higher Lp(a) concentrations because the liver secretes them more efficiently.

Mendelian randomization studies have clarified that Lp(a) molar concentration rather than apo(a) size is the primary determinant of cardiovascular risk (Gudbjartsson et al., 2019). Two people with identical Lp(a) concentrations face similar risks regardless of whether their particles are large or small. This finding has important implications for therapy: reducing the number of Lp(a) particles should reduce risk regardless of isoform size.

However, isoform size does complicate measurement. Mass-based assays (reported in mg/dL) can be confounded by apo(a) size because larger isoforms weigh more per particle. Molar-based assays (reported in nmol/L) count particles more directly and are increasingly preferred for clinical decision-making (Kronenberg et al., 2022).

What is the relationship between Lp(a) mass and particle number?

Lp(a) is reported in two different units that don’t convert cleanly. Mass concentration (mg/dL) measures the total mass of Lp(a) particles, while molar concentration (nmol/L) measures the number of particles. The conversion factor varies depending on apo(a) isoform size, making direct translation problematic.

For clinical purposes, a rough approximation suggests that 2.5 mg/dL roughly equals 1 nmol/L, but this ratio can range from 1.5 to 3.5 depending on the individual’s predominant isoform. The European Atherosclerosis Society recommends using isoform-insensitive assays and reporting in nmol/L when possible to minimize measurement variability (Kronenberg et al., 2022).

For patients trying to interpret their results, the key thresholds remain consistent: Lp(a) above 50 mg/dL or 125 nmol/L is considered elevated and associated with increased cardiovascular risk. The testing section of this guide provides more detail on assay selection and interpretation.

Why is Lp(a) both a lipid and thrombotic risk factor?

Lp(a) earns its dual classification because apolipoprotein(a) structurally mimics plasminogen, the inactive precursor to the enzyme that dissolves blood clots. When Lp(a) competes with plasminogen for binding sites on fibrin, it can interfere with the body’s ability to break down clots (Tsimikas, 2017). This prothrombotic effect compounds the atherosclerotic risk posed by Lp(a)‘s LDL-like core.

The LDL component of Lp(a) penetrates arterial walls just as regular LDL particles do, contributing to plaque formation through the same mechanisms. But the attached apo(a) amplifies the inflammatory response through oxidized phospholipids carried on its surface. These oxidized phospholipids activate immune cells and promote calcification in both coronary arteries and aortic valves (Capoulade et al., 2015).

The combination means elevated Lp(a) increases risk through multiple pathways simultaneously. This explains why Lp(a) is associated not only with heart attacks and strokes but also with peripheral artery disease and aortic stenosis, conditions that share both atherosclerotic and thrombotic components.

How does Lp(a) contribute to plaque formation?

Lp(a) particles enter the arterial wall through the same mechanisms as LDL, penetrating the endothelium and becoming trapped in the subendothelial space. Once there, the apoB-containing core can be oxidized, triggering the inflammatory cascade that characterizes atherosclerosis. Macrophages engulf the particles, transform into foam cells, and initiate plaque formation.

What distinguishes Lp(a) from LDL is the additional inflammatory burden from oxidized phospholipids on the apo(a) component. These OxPL molecules accelerate plaque progression and drive calcification processes in arterial and valvular tissue (Capoulade et al., 2015). The result is that Lp(a) particles may be more atherogenic per particle than equivalent LDL particles.

Mendelian randomization data support this interpretation. Genetic studies show that the cardiovascular risk reduction from lowering Lp(a) appears proportional to the absolute reduction in Lp(a) concentration (Emdin et al., 2016). This dose-response relationship strengthens the case for developing Lp(a)-lowering therapies.

What is the relationship between Lp(a) and aortic valve stenosis?

Calcific aortic valve stenosis, the progressive narrowing of the aortic valve due to calcium deposits, shares biological mechanisms with atherosclerosis. Elevated Lp(a) and its cargo of oxidized phospholipids have emerged as independent predictors of faster valve calcification and disease progression (Capoulade et al., 2015).

The mechanistic link involves the same OxPL molecules that drive arterial inflammation. On valve tissue, these oxidized lipids promote both inflammation and osteogenic differentiation, the process by which valve cells transform into bone-like tissue. The genetic evidence is compelling: Mendelian randomization studies show that lifelong exposure to lower Lp(a) reduces aortic stenosis risk by roughly 37% per standard deviation decrease (Emdin et al., 2016).

This relationship has clinical implications. Patients with elevated Lp(a) may benefit from echocardiographic monitoring for early valve changes. Whether Lp(a)-lowering therapies will prevent or slow aortic stenosis progression remains an open question awaiting trial results.

How is Lp(a) level genetically determined?

The LPA gene on chromosome 6 explains approximately 90% of the variation in Lp(a) levels between individuals. This makes Lp(a) one of the most heritable cardiovascular risk factors known. The primary genetic determinant is the number of kringle IV type 2 repeats, but numerous single nucleotide polymorphisms also influence production and clearance of the protein (Clarke et al., 2009).

Two specific SNPs have been extensively studied: rs10455872 and rs3798220. Both are associated with smaller apo(a) isoforms and higher Lp(a) levels. Carrying these variants significantly increases coronary disease risk even after adjusting for traditional risk factors. The genetic architecture confirms that elevated Lp(a) is causally related to cardiovascular events, not merely a bystander marker (Arsenault and Kamstrup, 2022).

The inheritance pattern is codominant, meaning each LPA allele contributes independently to your Lp(a) level. If you have elevated Lp(a), there is a high probability that first-degree relatives share elevated levels, making cascade screening within families a reasonable consideration.

Are there ethnic differences in Lp(a) levels?

Lp(a) levels vary substantially across populations. People of African descent have the highest median Lp(a) concentrations, with roughly 25% exceeding the 50 mg/dL threshold. South Asians also have elevated levels compared to European populations. The reasons are genetic: different populations carry different frequencies of LPA variants that influence Lp(a) production (Enas et al., 2019).

Importantly, the risk associated with elevated Lp(a) appears consistent across ethnicities. The same absolute Lp(a) concentration confers similar cardiovascular risk regardless of ancestry. This means that while elevated Lp(a) is more prevalent in some populations, the clinical implications of a given measurement remain universal.

The current recommendation to measure Lp(a) at least once in all adults applies across all ethnic groups. For populations with higher prevalence of elevated Lp(a), the yield of testing is proportionally greater, making the case for universal screening even stronger.

Conclusion

Lp(a) represents a distinct category of cardiovascular risk factor. Unlike most lipoproteins, its concentration is genetically determined and resistant to lifestyle modification. Unlike simple cholesterol measurements, its biology involves both atherosclerotic and thrombotic mechanisms. And unlike better-known risk factors, it remains widely undertested despite affecting roughly one billion people globally.

Understanding what Lp(a) is provides the foundation for understanding what it means for your health. The genetic nature of elevated Lp(a) explains why current treatments offer limited efficacy while simultaneously justifying the intensive development of targeted therapies. The unique structure of the particle, with its plasminogen-like component and oxidized phospholipid cargo, explains why Lp(a) damages both arteries and heart valves.

Most importantly, knowing that Lp(a) is genetically determined reframes the conversation from personal responsibility to proactive management. You didn’t choose your Lp(a) level. You can choose to measure it, understand it, and act on what you learn.